CDNA — CareDx, Inc.

Is CDNA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of October 3, 2026

CareDx, Inc. (CDNA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $67.15. The rating moved from Neutral to Overbought on September 29, 2026.

See all overbought Healthcare stocks →

AI analysis

CareDx is positioned as a leading provider of post-transplant molecular surveillance with recurring, subscription-like testing revenue and visible growth avenues from new assays and geographic expansion. Near-term upside is supported by transplant volume recovery and product commercialization, while downside is driven by reimbursement policy risk, competition, and execution on scale. Performance over the next month will hinge on quarterly results, any payer updates, and clearer visibility on international adoption.

Key factors

  • Leading market position in post-transplant surveillance with recurring revenue from molecular diagnostic tests (AlloSure and related offerings)
  • Installed-base growth and sticky customer relationships with transplant centers and specialty labs support predictable revenue streams
  • Product pipeline and commercial expansion (new assays, lab services, and international rollout) provide multi-quarter growth catalysts
  • Favorable secular trends: increasing transplant volumes, aging populations, and heightened focus on graft monitoring and personalized care
  • Improving margin profile and operational leverage potential as testing volumes scale and fixed costs are absorbed
  • Defensive characteristics vs. cyclical healthcare: revenue less correlated to elective procedure cycles, which can attract flows in risk-off periods

Risks

  • Reimbursement pressure and payer policy changes (including broader Medicare/MA dynamics) that could compress pricing or limit coverage for diagnostic tests
  • Intensifying competition from established labs, new molecular diagnostics entrants, or alternative monitoring technologies
  • Execution risk on international expansion, new product launches, and scaling of lab operations leading to slower-than-expected revenue realization
  • Regulatory or clinical setbacks (e.g., negative study results, labeling changes or inspection issues) that could damage adoption
  • Macro-driven risk aversion and capital-market volatility impairing funding access or weighing on multiple healthcare valuations
  • Supply chain or lab capacity constraints that could limit ability to meet demand during growth periods
  • Concentration risk tied to transplant market size and timing of transplant volumes (sensitivity to changes in hospital procedural mix)
  • Quarterly volatility around guidance/earnings that can lead to sharp price moves despite underlying multi-quarter trends

See today's live rating, score and targets

Members see the live hourly rating for CDNA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.